all report title image
  • Published On : Dec 2021
  • Code : CMI4833
  • Industry : Pharmaceutical
  • Pages : 190
  • Formats :

Ankylosing spondylitis (AS) is a rare type of inflammation that mainly affects spine and can damage large joints of body. It causes inflammation in the spinal joints (vertebrae), thereby causing severe pain and discomfort. Over time, ankylosing spondylitis can cause some bones in the spine to fuse together, as a result of which the spine becomes less flexible. Symptoms of ankylosing spondylitis include pain and stiffness in the hips and lower back.

The global ankylosing spondylitis market is estimated to be valued at US$ 4,864.3 million in 2021 and is expected to exhibit a CAGR of 8.2% during the forecast period (2021-2028).

Figure 1.Global Ankylosing Spondylitis Market Share (%) in Terms of Value, by Drug Type, 2021

Ankylosing Spondylilitis  | Coherent Market Insights

Increasing prevalence of ankylosing spondylitis is expected to drive the market growth during the forecast period.

The increasing prevalence of ankylosing spondylitis is expected to drive the global ankylosis spondylitis market growth during the forecast period. For instance, according to an article published by ‘Frontiers in Medicine’ journal in March 2021, the epidemiological data in Taiwan stated that the prevalence of ankylosing spondylitis is 96.9 per 100,000 people.

CMI table icon

Ankylosing Spondylitis Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 4,864.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.2% 2028 Value Projection: US$ 8,460.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying anti-rheumatic drugs (DMARDs), TNF Inhibitors, Corticosteroids, Others
  • By Route of Administration: Oral, Parentral
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.

Growth Drivers:
  • The rising prevalence of ankylosing spondylitis
  • Increasing launch of biosimilars
  • Increasing research & development efforts being undertaken by key industry players to augment treatment options 
Restraints & Challenges:
  • High cost of treatment
  • Lack of skilled surgeons and physiotherapists 

Figure 2. Global Ankylosing Spondylitis Market Share (%), by Distribution Channel, 2021

Ankylosing Spondylilitis  | Coherent Market Insights

Increasing strategic alliances between the companies to develop or to expand the availability of drugs is expected to drive the market growth during the forecast period.

Key players in the market are focusing on inorganic growth strategies, such as partnerships and collaborations which is expected to drive the market growth during the forecast period.

For instance, in August 2021, Inmagene Biopharmaceuticals, a leading biotech company focused on the development of therapeutics for immunology-related diseases, and Affibody AB, a company developing innovative bi- and multi-specific next-generation biopharmaceuticals, working in a partnership, announced the successful dosing of the first patient in the global ASPIRE phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for treating ankylosing spondylitis (AS).

Global Ankylosing Spondylitis Market – Impact of Coronavirus (COVID-19) Pandemic

Accessing medical services can be challenging for people with ankylosing spondylitis during the COVID-19 pandemic. While some drugs for ankylosing spondylitis can be self-administered, some are given through an IV in hospitals. Similarly, physical therapy requires a visit to the physical therapist, which has been difficult due to the COVID-19 pandemic.

Biologics such as TNF (Tumor Necrosis factor) inhibitors, used in ankylosing spondylitis treatment, may increase the risk of infections and lower the body's ability to fight infections, including COVID-19, because these medications cause a suppressing effect on the immune system. Biologics including IL-17 and IL-12/23 inhibitors are used for treating ankylosing spondylitis, but have the same immunosuppressive effect that may increase the risk of infections. Thus, due to this, the growth of the global ankylosing spondylitis market is expected to be hampered.

Ankylosing spondylitis is an immune-mediated inflammatory disease (IMID). According to a study conducted in Ontario, Canada, in 2020, it was found that people with IMIDs were tested for COVID-19 at a 20% higher rate, as compared to the general population.

Global Ankylosing Spondylitis Market: Restraint

The major factors that are expected to hinder growth of the global ankylosing spondylitis market include high cost of treatment and lack of skilled surgeons and physiotherapists.

Key Players

Major players operating in the global ankylosing spondylitis market include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.

Ankylosing spondylitis is an inflammation (chronic inflammatory arthritis) that mostly affects the spine. It generally causes stiffness and pain in the back. Over time, movement of the back gradually becomes limited as the bones of the spine become fused. This fusion is called ankylosing. Ankylosing spondylitis can also involve other joints such as the hips, shoulders and sometimes knees. Over time, it can affect the joints between the ribs and spine, restricting the movement of the chest and causing a difficulty in breathing deeply. Symptoms of ankylosing spondylitis include frequent pain and stiffness in buttocks and the lower back, which comes on progressively after a few weeks or months. At first, discomfort may be felt only on one side, or alternate sides. The pain is usually diffuse and dull, rather than localized. Other symptoms in the early stages include loss of appetite, mild fever, and general discomfort. Currently, there is no cure for AS, but there are treatments and drugs available to manage pain and reduce symptoms.

Market Dynamics

The increasing launches of new drugs for ankylosing spondylitis are expected to drive the market growth during the forecast period. For instance, in November 2021, Pfizer’s XELJANZ (tofacitinib) received marketing authorization by the European Commission, in the European Union for the treatment of active ankylosing spondylitis. It received approval for the administration of 5 mg XELJANZ (tofacitinib) twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have not responded adequately to conventional therapy. The approval of XELJANZ for ankylosing spondylitis was based on the data obtained from a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of XELJANZ (tofacitinib) 5 mg twice daily versus placebo in 269 adult patients with active ankylosing spondylitis.

Key features of the study:

  • This report provides an in-depth analysis of the global ankylosing spondylitis market, provides market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ankylosing spondylitis market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global ankylosing spondylitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ankylosing spondylitis market

Detailed Segmentation:

  • Global Ankylosing Spondylitis Market, By Drug Type:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Disease-modifying Anti-rheumatic Drugs (DMARDs)
    • TNF Inhibitors
    • Corticosteroids
    • Others
  • Global Ankylosing Spondylitis Market, By Route of Administration:
    • Oral
    • Parentral
  • Global Ankylosing Spondylitis Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Ankylosing Spondylitis Market, By Region:
    • North America
      • Drug Type
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • TNF Inhibitors
        • Corticosteroids
        • Others
      • Route of Administration
        • Oral
        • Parentral
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • Drug Type
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • TNF Inhibitors
        • Corticosteroids
        • Others
      • Route of Administration
        • Oral
        • Parentral
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Drug Type
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • TNF Inhibitors
        • Corticosteroids
        • Others
      • Route of Administration
        • Oral
        • Parentral
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Drug Type
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • TNF Inhibitors
        • Corticosteroids
        • Others
      • Route of Administration
        • Oral
        • Parentral
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Drug Type
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • TNF Inhibitors
        • Corticosteroids
        • Others
      • Route of Administration
        • Oral
        • Parentral
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Drug Type
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Disease-modifying Anti-rheumatic Drugs (DMARDs)
        • TNF Inhibitors
        • Corticosteroids
        • Others
      • Route of Administration
        • Oral
        • Parentral
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Amgen Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AbbVie Inc.
    • Pfizer Inc.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • CELGENE CORPORATION
    • Eli Lilly and Company
    • Cipla Inc.
    • Emcure Pharmaceuticals
    • Torrent Pharmaceuticals Ltd.
    • UCB S.A.
    • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
    • HENGRUI USA
    • Johnson & Johnson Services, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global ankylosing spondylitis market size is estimated to be valued at US$ 4,864.3 million in 2021 and is expected to exhibit a CAGR of 8.2% between 2021 and 2028.
Factors such as rising prevalence of ankylosing spondylitis, increasing launch of biosimilars, and increasing research & development efforts being undertaken by key industry players to augment treatment options are expected to drive growth of the market during the forecast period.
Nonsteroidal anti-inflammatory drugs (NSAIDs) drug type segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include high cost of treatment and lack of skilled surgeons and physiotherapists.
Major players operating in the market include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo